May 16: The Week in Cancer News
Study examines benefit of PARP inhibitors before surgery in BRCA-related breast cancer, and exercise improves sexual function after prostate cancer treatment.
Progress Against Cancer
Study examines benefit of PARP inhibitors before surgery in BRCA-related breast cancer, and exercise improves sexual function after prostate cancer treatment.
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer.
The largest increases were found in breast, colorectal, endometrial, pancreatic, and kidney cancers. Early-onset cancers, or cancers diagnosed in individuals under the age of 50, are rising in the United States. While the exact...
The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved retifanlimab-dlwr (Zynyz) for patients with...
The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult...
The FDA has approved belzutifan for certain patients with pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has approved belzutifan (Welireg) for the treatment of patients 12 years and older with locally...
During the Presidential Select Symposium at the AACR Annual Meeting 2025, Patricia M. LoRusso, DO, PhD(h), FAACR, led a panel addressing the global cancer burden.
A single dose of HPV vaccine is highly effective, and not all cancers are increasing in people under 50.
For April 2025, the editors of AACR's 10 journals highlighted studies on evolution in glioblastoma, new cancer treatment approaches, and more.
The FDA has approved avutometinib and defactinib for certain patients with KRAS-mutated low-grade serous ovarian cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More